Literature DB >> 7575699

Causes of death in systemic lupus erythematosus. Long-term followup of an inception cohort.

M M Ward1, E Pyun, S Studenski.   

Abstract

OBJECTIVE: To describe the causes of death in a cohort of patients with systemic lupus erythematosus (SLE), and to determine if the major causes of death differ according to patient age, sex, race, socioeconomic status, and the duration of SLE.
METHODS: We examined survival in a cohort of 408 patients with SLE. During a median of 11 years of followup, 144 patients died. The cause of death was determined for 134 patients (93%).
RESULTS: SLE was the most common cause of death, occurring in 49 patients (34%), followed by infection (n = 32; 22%), cardiovascular disease (n = 23; 16%), cerebrovascular disease (n = 8; 6%), and cancer (n = 8; 6%). Deaths due to SLE and due to infections were more common among younger patients, and deaths due to cancer were more common among older patients. Although the risk of death due to SLE was greatest during the first 3 years after diagnosis, deaths due to SLE occurred throughout the course of disease.
CONCLUSION: In this study of patients with SLE who were followed up for an extended period of time beginning soon after diagnosis, SLE was the most common cause of death, and deaths due to SLE occurred throughout the course of illness.

Entities:  

Mesh:

Year:  1995        PMID: 7575699     DOI: 10.1002/art.1780381016

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  38 in total

1.  Childhood-onset disease as a predictor of mortality in an adult cohort of patients with systemic lupus erythematosus.

Authors:  Aimee O Hersh; Laura Trupin; Jinoos Yazdany; Peter Panopalis; Laura Julian; Patricia Katz; Lindsey A Criswell; Edward Yelin
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-08       Impact factor: 4.794

2.  Survival study by organ disorders in 306 Japanese patients with systemic lupus erythematosus: results from a single center.

Authors:  M Funauchi; H Shimadzu; C Tamaki; T Yamagata; Y Nozaki; M Sugiyama; S Ikoma; K Kinoshita
Journal:  Rheumatol Int       Date:  2006-08-31       Impact factor: 2.631

3.  [Cardiovascular monitoring of patients with systemic lupus erythematosus].

Authors:  H Schotte; H Becker; W Domschke; M Gaubitz
Journal:  Z Rheumatol       Date:  2005-11       Impact factor: 1.372

4.  QT dispersion in patients with systemic lupus erythematosus: the impact of disease activity.

Authors:  Javad Kojuri; Mohammad Ali Nazarinia; Mohammad Ghahartars; Yadollah Mahmoody; Gholam reza Rezaian; Lida Liaghat
Journal:  BMC Cardiovasc Disord       Date:  2012-02-27       Impact factor: 2.298

Review 5.  [Changes in mortality and morbidity in systemic lupus erythematosus].

Authors:  G Chehab; R Fischer-Betz; M Schneider
Journal:  Z Rheumatol       Date:  2011-08       Impact factor: 1.372

6.  Stress Intervention and Disease in African American Lupus Patients: The Balancing Lupus Experiences with Stress Strategies (BLESS) Study.

Authors:  Edith M Williams; Diane Kamen; Megan Penfield; James C Oates
Journal:  Health (Irvine Calif)       Date:  2014-01

7.  Ethnic disparities among patients with systemic lupus erythematosus in South Carolina.

Authors:  Erica Anderson; Paul J Nietert; Diane L Kamen; Gary S Gilkeson
Journal:  J Rheumatol       Date:  2008-03-15       Impact factor: 4.666

8.  Fatal infection in children with lupus nephritis treated with intravenous cyclophosphamide.

Authors:  Kamolwish Laoprasopwattana; Pornsak Dissaneewate; Prayong Vachvanichsanong
Journal:  Pediatr Nephrol       Date:  2009-03-12       Impact factor: 3.714

9.  Short-term perioperative all-cause mortality and cardiovascular events in women with systemic lupus erythematosus.

Authors:  Ali Yazdanyar; Mary Chester Wasko; Lisabeth V Scalzi; Kevin L Kraemer; Michael M Ward
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-06       Impact factor: 4.794

Review 10.  [Modern therapy for systemic lupus erythematosus].

Authors:  R Fischer-Betz; M Schneider
Journal:  Z Rheumatol       Date:  2007-12       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.